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Summary
Background Endometriosis is a risk factor for epithelial ovarian cancer; however, whether this risk extends to all 
invasive histological subtypes or borderline tumours is not clear. We undertook an international collaborative study to 
assess the association between endometriosis and histological subtypes of ovarian cancer.
Methods Data from 13 ovarian cancer case–control studies, which were part of the Ovarian Cancer Association 
Consortium, were pooled and logistic regression analyses were undertaken to assess the association between self-
reported endometriosis and risk of ovarian cancer. Analyses of invasive cases were done with respect to histological 
subtypes, grade, and stage, and analyses of borderline tumours by histological subtype. Age, ethnic origin, study site, 
parity, and duration of oral contraceptive use were included in all analytical models.
Findings 13 226 controls and 7911 women with invasive ovarian cancer were included in this analysis. 818 and 738, 
respectively, reported a history of endometriosis. 1907 women with borderline ovarian cancer were also included in 
the analysis, and 168 of these reported a history of endometriosis. Self-reported endometriosis was associated with a 
signiﬁ cantly increased risk of clear-cell (136 [20·2%] of 674 cases vs 818 [6·2%] of 13 226 controls, odds ratio 3·05, 
95% CI 2·43–3·84, p<0·0001), low-grade serous (31 [9·2%] of 336 cases, 2·11, 1·39–3·20, p<0·0001), and endometrioid 
invasive ovarian cancers (169 [13·9%] of 1220 cases, 2·04, 1·67–2·48, p<0·0001). No association was noted between 
endometriosis and risk of mucinous (31 [6·0%] of 516 cases, 1·02, 0·69–1·50, p=0·93) or high-grade serous invasive 
ovarian cancer (261 [7·1%] of 3659 cases, 1·13, 0·97–1·32, p=0·13), or borderline tumours of either subtype (serous 
103 [9·0%] of 1140 cases, 1·20, 0·95–1·52, p=0·12, and mucinous 65 [8·5%] of 767 cases, 1·12, 0·84–1·48, p=0·45).
Interpretation Clinicians should be aware of the increased risk of speciﬁ c subtypes of ovarian cancer in women with 
endometriosis. Future eﬀ orts should focus on understanding the mechanisms that might lead to malignant 
transformation of endometriosis so as to help identify subsets of women at increased risk of ovarian cancer.
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German Cancer Research Centre, Eve Appeal, Oak Foundation, UK National Institute of Health Research, National 
Health and Medical Research Council of Australia, US Army Medical Research and Materiel Command, Cancer 
Council Tasmania, Cancer Foundation of Western Australia, Mermaid 1, Danish Cancer Society, and Roswell Park 
Alliance Foundation.
Introduction
Endometriosis is a common gynaecological disorder that 
is characterised by ectopic growth of endometrial glands 
and stroma. The estimated prevalence in the general 
population, based on women undergoing tubal ligation, 
is about 4%; however, the disease is much more common 
in women with pelvic pain or infertility.1 The disease 
process typically involves the surface of the ovaries and 
pelvic peritoneum and is commonly thought to be due to 
reﬂ ux of endometrial tissue through the fallopian tubes 
during menstruation. Endometriosis might cause pelvic 
inﬂ ammation, adhesions, chronic pain, and infertility, 
though such sequelae generally subside after menopause 
because growth of endometriotic tissue is oestrogen 
dependent.2 An altered immune response is proposed to 
play a part in endometriosis.3 Generally, the results of 
epidemiological studies have consistently shown that 
endometriosis is associated with an increase in risk of 
invasive epithelial ovarian cancer, the most fatal 
malignancy of the female reproductive system.4–14 
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How ever, this association was not noted in two studies: 
one a prospective cohort and the other analysing patients 
at an infertility clinic.15,16
Invasive epithelial ovarian cancer consists of ﬁ ve major 
histological subgroups—clear-cell, endometrioid, 
mucinous, high-grade serous, and low-grade serous,17 
which show distinct molecular, clinical, and pathological 
characteristics.18 Evidence suggests that the risk 
associated with endometriosis might vary according to 
the subtype.19–22 Investigators have generally noted a 
stronger association between a self-reported history of 
endometriosis and endometrioid and clear-cell subtypes 
of invasive ovarian cancer,4,5,9,14 although this association 
has not been observed in all studies.8 Results of studies 
that investigated the synchronous presence of ovarian 
cancer and endometriosis have also consistently shown 
increased occurrence of endometriosis in women with 
endometrioid and clear-cell cancer relative to the other 
subtypes.23
The Ovarian Cancer Association Consortium (OCAC) 
was founded in 2005 to foster collaborative eﬀ orts to 
discover and validate associations between genetic poly-
morphisms and risk of ovarian cancer.24,25 The construc-
tion of a centralised OCAC database of information 
about common risk factors also provides an opportunity 
to improve characterisation of epidemiological associa-
tions within histological subsets and according to 
tumour behaviour, stage, and grade. To estimate the 
consistency and magnitude of the association between 
endometriosis and risk of the ﬁ ve major histological 
subtypes of invasive epithelial ovarian cancer and 
borderline tumours with greater statistical power than 
has been possible previously, we undertook a pooled 
analysis of 13 case–control studies.
Methods
Patients and procedures
All studies included in this pooled analysis had approval 
from ethics committees, and written informed consent 
was obtained from all study participants. Study 
characteristics are reported in the appendix.
We used primary data from all studies in the OCAC 
at the time this analysis was initiated; the study question-
naires included questions about endometriosis. Data for 
endometriosis were reported in 13 case–control studies 
of ovarian cancer. One study was undertaken in 
Australia,9 three in Europe,26–28 and nine in the USA.5,8,29–36 
The characteristics of the 13 studies are presented in 
table 1. Data for endometriosis were self-reported in all 
studies. Women with missing endometriosis data and 
those with non-epithelial tumours were excluded. Data 
for origin of endometriosis (endo metrioma, peritoneal, 
or deep inﬁ l trating disease) were not available. Our 
analysis dataset consisted of data from 23 144 women 
(7911 with invasive ovarian cancer, 1907 with borderline 
ovarian cancer, and 13 326 controls). Subsets of data from 
ﬁ ve studies have been reported previously (Australian 
Cancer Study, Australian Ovarian Cancer Study [AUS],9 
Diseases of the Ovary and their Evaluation Study [DOV],5 
Hawaii Ovarian Cancer Study [HAW],7 Malignant 
Ovarian Cancer Study [MAL],7 and University of Southern 
California, Study of Lifestyle and Women’s Health 
[USC]8). We excluded one OCAC study (from Poland37) 
from this analysis because the investigators thought that 
the endometriosis data were not reliable.
In each study, information was provided about poten-
tial confounding variables that were previously noted to 
be related to ovarian cancer risk: age, ethnic origin, parity, 
breastfeeding, duration of oral contraceptive use, family 
history of ovarian cancer, weight, height, and history of 
tubal ligation. All data were cleaned and checked for 
internal consistency and clariﬁ cations were requested 
from the original investigators when needed.
Statistical analysis
We included age, ethnic origin, oral contraceptive use, 
and parity in all models irrespective of their eﬀ ect on 
the association between endometriosis and ovarian 
cancer risk because these factors were judged to be 
potentially important confounders a priori. Age was 
grouped into 5 year categories (<39 years, 40–44 years, 
45–49 years, 50–54 years, 55–59 years, 60–64 years, 
65–69 years, 70–74 years, and ≥75 years); ethnic origin 
was categorised as non-Hispanic white, Hispanic white, 
black, Asian, or other. Asian and other ethnic groups are 
heterogeneous, but results were not changed irrespective 
of whether these groups were included in the analyses. 
Number of births was categorised as zero, one, two, 
three, and four or more; and oral contraceptive use was 
categorised as never, less than 2 years, 2–4·99 years, 
5–9·99 years, and at least 10 years of use. The 
confounding eﬀ ects of breastfeeding, weight, height, 
body-mass index, tubal ligation, and family history of 
ovarian cancer were also considered.
Odds ratios (ORs), with corresponding 95% CIs, were 
calculated by use of conditional logistic regression to 
represent the magnitude of association between 
endometriosis and risk of ovarian cancer (overall and 
within each subtype) for each study site stratiﬁ ed (ie, 
matched) by age and ethnic origin and adjusted for oral 
contraceptive use and parity with SAS (version 9.2). 
When a study had a cell with zero (table 2), which 
occurred only in the cells for exposed cases, we used the 
Peto method to calculate the OR.38 We did not use the 
Peto method to calculate 95% CIs because this method 
is known to be biased with non-balanced data, instead 
we used the exact conﬁ dence intervals.38 The study-
speciﬁ c ORs were then used to calculate the summary 
ORs. Subtype analyses were done for cancer behaviour 
(invasive or borderline) and histological subtype (clear-
cell, endometrioid, mucinous, and serous) for invasive 
cases. The invasive serous tumours were categorised as 
low-grade (I) and high-grade (II–IV) based on the 
prevailing view that these are separate subtypes.17 We 
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also analysed low-grade and high-grade endometrioid 
tumours separately because they might behave 
diﬀ erently based on grade.39 In the analysis of borderline 
tumours, only serous and mucinous borderline cancers 
were analysed since clear-cell and endometrioid 
borderline tumours are rare, with insuﬃ  cient numbers 
for a mean ingful analysis. Histological type-speciﬁ c 
associations were assessed by comparison of each 
subtype with the controls. Additionally, we undertook 
case–case analyses to assess whether the histological 
subtypes diﬀ ered from each other. A series of outcome 
variables for each comparison of histological subtype 
was created for this analysis—eg, serous high-grade 
compared with serous low-grade.
A sensitivity analysis was also done to investigate 
whether the association between ovarian cancer risk and 
endo metriosis diﬀ ered based on the timing of diagnosis 
of endometriosis relative to diagnosis date of ovarian 
cancer for cases and reference date for controls. For this 
analysis, we coded study participants as not having 
endometriosis if they were diagnosed with endometriosis 
within 3 years, 5 years, or 10 years of their ovarian cancer 
diagnosis or reference date for controls in the seven 
studies (AUS,9 DOV,5 German Ovarian Cancer Study 
[GER],26 Hormones and Ovarian Cancer Prediction Study 
[HOP],31 North Carolina Ovarian Cancer Study [NCO],33 
New England Case-Control Study of Ovarian Cancer 
[NEC],34 USC8,36) where this information was available. All 
p values were two-sided.
Role of the funding source
No funding agency or sponsor had any role in the design 
and conduct of the study, collection, management, 
analysis, and interpretation of the data, and preparation, 
review, or approval of the report. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
In the pooled analysis, 738 (9·3%) of 7911 women with 
invasive epithelial ovarian cancer and 168 (8·8%) of 
1907 with borderline ovarian cancer reported a history 
of endometriosis (table 2). 818 (6·2%) of 13 226 controls 
reported a history of endometriosis (table 2). A history 
of endometriosis was reported by 136 (20·2%) of 
674 women with clear-cell, 169 (13·9%) of 1220 with 
endometrioid, 31 (6·0%) of 516 with mucinous, 
261 (7·1%) of 3659 with high-grade serous, and 
31 (9·2%) of 336 with low-grade serous subtypes of 
invasive ovarian cancer. 103 (9·0%) of 1140 women with 
borderline serous and 65 (8·5%) of 767 with borderline 
mucinous tumours reported a history of endometriosis. 
Breastfeeding, weight, height, body-mass index, tubal 
Study name Study 
abbreviation
Study type Method of data collection Ascertainment 
period
Asia-Paciﬁ c
Australia Australian Cancer Study*†, Australian 
Ovarian Cancer Study*†9
AUS Population based Self-completed questionnaire, 
checked by trained research nurse
2002–06
Europe
Germany German Ovarian Cancer Study†26 GER Population based Self-completed questionnaire 1992–98
Denmark Malignant Ovarian Cancer Study27 MAL Population based In-person or phone interview 1994–99
UK United Kingdom Ovarian Cancer 
Population Study28
UKO Population based Self-completed questionnaire 2006–07
USA
CT Connecticut Ovary Study29 CON Population based In-person interview 1999–2003
WA Diseases of the Ovary and their Evaluation 
Study†5
DOV Population based In-person interview 2002–05
HI Hawaii Ovarian Cancer Study30 HAW Population based In-person interview 1994–2007
Western PA, northeast 
OH, western NY
Hormones and Ovarian Cancer Prediction 
Study†31
HOP Population based In-person interview 2003–08
North central states 
(MN, SD, ND, IL, IA, WI)
Mayo Clinic Ovarian Cancer Study32 MAY Clinic based In-person interview 2000–08
NC North Carolina Ovarian Cancer Study†33 NCO Population based In-person interview 1999–2008
NH and eastern MA New England Case-Control Study of 
Ovarian Cancer†34
NEC Population based In-person interview 1999–2008
Orange County and 
San Diego County, CA
University of California, Irvine Ovarian 
Cancer Study35
UCI Population based Self-completed questionnaire 1995–2005
Los Angeles County, CA University of Southern California, Study of 
Lifestyle and Women’s Health†8,36
USC Population based In-person interview 1993–2005
*Combined for the purpose of the analysis. †Data for timing of endometriosis available.
Table 1: Description of studies included in the analysis
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ligation, and family history of ovarian cancer did not 
confound the association between endometriosis and 
ovarian cancer-risk (β coeﬃ  cient changed by <10%) and 
were not considered further in the analysis (data not 
shown).
No association was noted between a history of 
endometriosis and borderline ovarian cancer (both 
serous and mucinous subtypes; table 3). By contrast, a 
history of endometriosis was associated with an increased 
risk of invasive epithelial ovarian cancer, after taking 
study site, age, ethnic origin, oral contraceptive use, and 
parity into account (table 3). This result was consistently 
noted for the 13 studies (ﬁ gure 1), although GER, which 
had very few exposed cases, had a summary estimate of 
less than one.
Association of endometriosis and risk diﬀ ered for the 
histological subtypes of invasive epithelial ovarian 
cancer. Women who reported a history of endometriosis 
were more likely to develop invasive low-grade serous, 
endometrioid, and clear-cell ovarian cancer (table 3; 
ﬁ gure 2) relative to women without such a history. 
A history of endometriosis was not associated with 
invasive mucinous ovarian cancer (table 3; ﬁ gure 2) or 
invasive serous high-grade ovarian cancer (table 3; 
ﬁ gure 2). No signiﬁ cant heterogeneity of eﬀ ects was 
noted for any of the invasive histological subtypes 
(ﬁ gure 2).
Case–case analyses showed that a history of endo-
metriosis was more commonly reported by women with 
invasive clear-cell, serous low-grade, and endometrioid 
ovarian cancers than by women with invasive serous high-
grade or invasive mucinous ovarian cancers (all comparisons 
p<0·02). Endometriosis was more strongly linked with 
invasive clear-cell ovarian cancer than with the invasive 
endometrioid subtype (OR 1·64, 95% CI 1·21–2·22, 
p=0·001). Also, endometriosis was more strongly linked 
with invasive low-grade serous ovarian cancer than with its 
high-grade counterpart (1·94, 1·21–3·11, p=0·01).
Additional analyses of histological subtypes to assess 
the role of stage and grade (for clear-cell, endometrioid, 
and mucinous ovarian cancers) in the endometriosis–
invasive epithelial ovarian cancer relation showed no 
diﬀ erences (data not shown).
We analysed whether the eﬀ ect was robust to exclusion 
of women who were diagnosed with endometriosis 
within close proximity (calendar time) to diagnosis of 
their ovarian cancer. Information about the timing of the 
diagnosis of endometriosis relative to that of invasive 
epithelial ovarian cancer was available in seven studies 
(5674 cases, 8968 controls). When women with 
endometriosis who were diagnosed within 3 years of 
their ovarian cancer diagnosis for cases and reference 
date for controls were coded as not having endometriosis, 
the results were slightly attenuated versus those without 
restrictions on the timing of diagnosis of endometriosis 
relative to diagnosis of ovarian cancer, but remained 
strong (table 4). These associations remained when the 
period between endometriosis diagnosis and ovarian 
cancer diagnosis for cases and reference date for controls 
was increased to 5 years or 10 years (table 4).
Discussion
Our ﬁ ndings suggest that the association of a history of 
endometriosis with increased risk of ovarian cancer is 
only apparent for invasive low-grade serous, clear-cell, 
and endometrioid subtypes, thus providing information 
about the pathogenesis of these subtypes relative to other 
subtypes of invasive epithelial ovarian cancer and further 
emphasising the diﬀ erences between low-grade and 
high-grade serous cancers.
The relation between endometriosis and serous 
ovarian cancer has generally been null; however, this 
subtype has not been analysed according to grade in 
previous studies.5,9,14 By contrast, we note an association 
between endometriosis and increased risk of low-grade 
serous ovarian cancers. Results of recent molecular 
genetic studies have suggested that low-grade and high-
grade serous ovarian cancers are distinct—high-grade 
cases are characterised by TP53 mutations, whereas 
low-grade cases typically have KRAS or BRAF 
mutations.18,40 Likewise, increasing evidence lends 
support to the hypothesis that a signiﬁ cant proportion 
of low-grade serous tumours can develop from 
borderline precursors, whereas this is not the case for 
high-grade serous tumours.40 Thus, the pathogenesis of 
low-grade and high-grade serous ovarian cancers might 
diﬀ er. Although concomitant endometriosis is often 
noted in endo metrioid and clear-cell ovarian cancers, 
some low-grade serous cancers might arise in 
endosalpingiosis (benign glandular proliferations), 
which is thought to be of tubal origin. Because 
endosalpingiosis is asymptomatic, its presence can only 
be detected patho logically and its incidence cannot be 
Crude Stratiﬁ ed only Stratiﬁ ed and adjusted
OR (95% CI) p value OR (95% CI)* p value OR (95% CI)† p value
Invasive 1·49 (1·34–1·65) <0·0001 1·53 (1·37–1·70) <0·0001 1·46 (1·31–1·63) <0·0001
Clear-cell 3·73 (3·04–4·58) <0·0001 3·44 (2·78–4·27) <0·0001 3·05 (2·43–3·84) <0·0001
Endometrioid 2·32 (1·94–2·78) <0·0001 2·20 (1·82–2·66) <0·0001 2·04 (1·67–2·48) <0·0001
Mucinous 1·09 (0·76–1·58) 0·63 1·04 (0·71–1·51) 0·86 1·02 (0·69–1·50) 0·93
High-grade 
serous
1·11 (0·96–1·29) 0·16 1·16 (1·00–1·35) 0·056 1·13 (0·97–1·32) 0·13
Low-grade 
serous
2·02 (1·38–2·97) <0·0001 2·22 (1·48–3·31) <0·0001 2·11 (1·39–3·20) <0·0001
Borderline 1·26 (1·05–1·50) 0·012 1·19 (0·99–1·43) 0·062 1·12 (0·93–1·35) 0·24
Mucinous 1·27 (0·97–1·67) 0·078 1·19 (0·90–1·57) 0·23 1·12 (0·84–1·48) 0·45
Serous 1·31 (1·05–1·63) 0·015 1·28 (1·02–1·61) 0·034 1·20 (0·95–1·52) 0·12
OR=odds ratio. *Stratiﬁ ed by age (5 year categories), ethnic origin (non-Hispanic white, Hispanic white, black, Asian, 
and other). †Stratiﬁ ed by age (5 year categories), ethnic origin (non-Hispanic white, Hispanic white, black, Asian, and 
other), and adjusted for duration of oral contraceptive use (never, <2 years, 2–4·99 years, 5–9·99 years, ≥10 years), and 
parity (0, 1, 2, 3, ≥4 children).
Table 3: Association between history of endometriosis and the histological subtypes of ovarian cancer
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ascertained in case–control studies. We speculate that 
perhaps the processes of endometriosis and 
endosalpingiosis result from a similar underlying host 
susceptibility to implantation of exfoliated Müllerian 
epithelial cells from both the endometrium and fallopian 
tube. Our ﬁ ndings of an association with endometriosis 
suggest that we might have identiﬁ ed a second precursor 
lesion for low-grade serous ovarian cancer in addition to 
borderline serous precursors.
Although the risk associated with a history of endo-
metriosis was increased for both invasive clear-cell and 
endometrioid ovarian cancers, case–case comparisons 
suggested a stronger association for endometriosis with 
clear-cell cancer than with the endometrioid subtype. 
However, this diﬀ erence might result from the inclusion 
of misclassiﬁ ed high-grade serous cases within the group 
of endometrioid cases. The pathological slides from the 
cases in this study have not undergone a systematic re-
review and thus some misclassiﬁ cation is likely to be 
present.17 In a systematic review of 176 endometrioid 
cases, 50 (28%) were reclassiﬁ ed as high-grade serous.17 
Assuming our endometrioid cases also included 28% 
high-grade serous cases and assuming an OR of 1 for 
high-grade serous disease and endometriosis, the 
association we noted between endometriosis and endo-
metrioid ovarian cancers might have been attenuated 
from an OR of 2·50 to 2·04. Additionally, misclassiﬁ cation 
of clear-cell tumours as low-grade invasive serous ovarian 
cancer might, partly, account for the association noted 
for this subtype with a history of endometriosis. Sangoi 
and colleagues41 reported 13 cases of clear-cell cancer as 
being misclassiﬁ ed as serous borderline tumours (ten 
cases) and low-grade serous (three cases);41 we did not 
note an association between endometriosis and serous 
borderline tumours and misclassiﬁ cation is unlikely to 
account for the magnitude of eﬀ ect with low-grade serous 
cancers.
Ness42 reviewed the evidence for endometriosis as a 
precursor lesion for ovarian cancer and proposed both 
inﬂ ammatory and hormonal pathways for this process. 
However, the steps in malignant transformation of 
ectopic endometrium still need to be understood. Many 
of the same genes, such as β catenin and PTEN, have 
been shown to be mutated in both endometrial cancers 
and endometrioid ovarian cancers,39 suggesting a shared 
molecular pathogenesis. However, clear-cell ovarian 
tumours do not express oestrogen or progesterone 
receptors and therefore endometriosis that can transform 
into clear-cell ovarian cancer could become hormone 
independent during the transformation process.18
Molecular similarities between synchronous endo-
metriosis and ovarian cancer at the time of diagnosis 
have been described.42 Mutations in the ARID1A gene 
have been noted in clear-cell tumours and contiguous 
atypical endometriosis, but not in distant endometriotic 
lesions.43 However, to our knowledge, no studies have 
been reported in which endometriotic lesions excised 
years before the development of cancer have been 
compared with tissue obtained at the time of cancer 
diagnosis. Such a comparison might provide a basis for 
identiﬁ cation of women with endometriosis who are at 
highest risk of ovarian cancer. Although we have 
reported strong associations between endometriosis 
and risk of low-grade serous, clear-cell, and endometrioid 
ovarian cancers, most women with endometriosis do 
not develop ovarian cancer. Identiﬁ cation of women 
with endometriosis who are at risk of cancer would 
provide a basis for increased cancer surveillance of the 
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Figure 1: Association between endometriosis and subtypes of ovarian cancer
(A) Invasive. (B) Borderline. Data are site-speciﬁ c stratiﬁ ed and adjusted ORs (squares) and 95% CI (horizontal 
lines). AUS=Australian Cancer Study, Australian Ovarian Cancer Study.9 GER=German Ovarian Cancer Study.26 
MAL=Malignant Ovarian Cancer Study.27 UKO=United Kingdom Ovarian Cancer Population Study.28 
CON=Connecticut Ovary Study.29 DOV=Diseases of the Ovary and their Evaluation Study.5 HAW=Hawaii Ovarian 
Cancer Study.30 HOP=Hormones and Ovarian Cancer Prediction Study.31 MAY=Mayo Clinic Ovarian Cancer Study.32 
NCO=North Carolina Ovarian Cancer Study.33 NEC=New England Case-Control Study of Ovarian Cancer.34 
UCI=University of California, Irvine Ovarian Cancer Study.35 USC=University of Southern California, Study of 
Lifestyle and Women’s Health.8,36 OR=odds ratio.
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Figure 2: Association between endometriosis and subtypes of invasive ovarian cancer
(A) Clear-cell. (B) Endometrioid. (C) Mucinous. (D) High-grade serous. (E) Low-grade serous. Data are site-speciﬁ c stratiﬁ ed and adjusted ORs (squares) and 95% CI (horizontal lines). AUS=Australian 
Cancer Study, Australian Ovarian Cancer Study.9 GER=German Ovarian Cancer Study.26 MAL=Malignant Ovarian Cancer Study.27 UKO=United Kingdom Ovarian Cancer Population Study.28 
CON=Connecticut Ovary Study.29 DOV=Diseases of the Ovary and their Evaluation Study.5 HAW=Hawaii Ovarian Cancer Study.30 HOP=Hormones and Ovarian Cancer Prediction Study.31 MAY=Mayo 
Clinic Ovarian Cancer Study.32 NCO=North Carolina Ovarian Cancer Study.33 NEC=New England Case-Control Study of Ovarian Cancer.34 UCI=University of California, Irvine Ovarian Cancer Study.35 
USC=University of Southern California, Study of Lifestyle and Women’s Health.8,36 OR=odds ratio.
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relevant population and potentially alter the treatment 
of their endometriosis. In this respect, Rossing and 
colleagues5 reported that the increased risk of 
endometrioid and clear-cell ovarian tumours associated 
with endometriosis was reduced among women who 
underwent ovarian surgery after the endometriosis was 
diagnosed.
The results in this report are from case–control studies 
in which the history of endometriosis was based on self 
reports. The frequency of endometriosis reported in the 
control participants in studies from Australia and the 
USA was much higher than it was in those from Europe 
(5·7–12·7% vs 1·0–4·2%; table 2). The reasons for this 
diﬀ erence in frequency are not clear. In two of three 
European studies (GER and UKO), data were collected 
by use of a self-completed questionnaire, and in the 
third European study (MAL) a trained study nurse 
collected the data, which suggests that the method of 
data collection did not contribute to the diﬀ erence. 
Perhaps more laproscopic surgeries for diagnosis of 
endometriosis were undertaken in Australia and the 
USA, which might account for the diﬀ erence in 
frequency. Endometriosis frequency in cases from the 
European studies was also low and overall the results of 
these studies did not contribute substantively to the 
weighted summary OR.
Recall bias is a major concern in case–control studies, 
particularly with a self-reported exposure like endo-
metriosis. Cases might have over-reported a history of 
endometriosis compared with controls, resulting in an 
overestimation of the OR. However, there is little reason 
to believe that this over-reporting would be non-random 
with respect to histological subtype of ovarian cancer and 
therefore it is unlikely to be an explanation for these 
results. This or other underlying biases are unlikely to 
account for these ﬁ ndings since the results across study 
populations were consistent. Also, results from registry-
based studies in Sweden and Denmark where endo-
metriosis data were obtained from hospital discharge 
databases were similar to our results in invasive cases10,14 
and by histological subtype.14
In this pooled analysis with primary data from 
13 studies, a self-reported history of endometriosis was 
associated with a signiﬁ cantly increased risk of invasive 
low-grade serous, clear-cell, and endometrioid ovarian 
cancers. An important consideration is whether these 
associations suggest a causal relation. The large sample 
size and narrow 95% CIs around ORs suggest that the 
associations we noted are unlikely to indicate chance 
alone. We were able to consider and control for a wide 
range of potential confounders. Our results were 
consistent for studies from various locations in Australia, 
Europe, and the USA that were undertaken in the 
1990s and 2000s and sensitivity analyses suggest that risk 
is increased even among women whose endo metriosis 
was diagnosed many years before their ovarian cancer 
(table 4). Although cases might have over-reported a 
history of endometriosis compared with controls, any 
such over-reporting is unlikely to result in ﬁ ndings of 
increased risk that is restricted to speciﬁ c histological 
subtypes. Further, our epidemiological ﬁ ndings are 
consistent with the existing laboratory evidence of the 
Clear-cell Endometrioid Low-grade serous
OR (95% CI)* p value OR (95% CI)* p value OR (95% CI)* p value
Exclusions
None 3·07 (2·44–3·86) <0·0001 2·05 (1·68–2·49) <0·0001 2·31 (1·50–3·55) <0·0001
≤3 years 2·78 (2·06–3·74) <0·0001 1·70 (1·30–2·24) <0·0001 2·01 (1·20–3·35) 0·008
≤5 years 2·51 (1·84–3·42) <0·0001 1·60 (1·21–2·13) 0·001 1·97 (1·17–3·34) 0·01
≤10 years 2·38 (1·71–3·33) <0·0001 1·49 (1·09–2·03) 0·01 1·88 (1·06–3·32) 0·03
Data reported for the seven studies with information about timing of diagnosis (AUS, DOV, GER, HOP, NCO, NEC, and 
USC). OR=odds ratio. AUS=Australian Cancer Study, Australian Ovarian Cancer Study.9 DOV=Diseases of the Ovary and 
their Evaluation Study.5 GER=German Ovarian Cancer Study.26 HOP=Hormones and Ovarian Cancer Prediction Study.31 
NCO=North Carolina Ovarian Cancer Study.33 NEC=New England Case-Control Study of Ovarian Cancer.34 USC=University 
of Southern California, Study of Lifestyle and Women’s Health.8,36 *Stratiﬁ ed according to age (5 year categories), ethnic 
origin (non-Hispanic white, Hispanic white, black, Asian, and other), and adjusted for duration of oral contraceptive use 
(never, <2 years, 2–4·99 years, 5–9·99 years, and ≥10 years), and parity (0, 1, 2, 3, and ≥4 children).
Table 4: Sensitivity analysis for the association between endometriosis and risk of invasive ovarian 
cancer based on timing of diagnosis between the two diseases
Panel: Research in context
Systematic review
To assess the association between ovarian cancer-risk and endometriosis, we searched 
PubMed for English language papers published during 1973–2011. We used the search 
terms “ovarian cancer risk” and “endometriosis”. We then assessed the resulting 
225 articles for relevance to our topic. Additional reports identiﬁ ed from the articles 
found during the initial search were reviewed for relevance.
Interpretation
Based on our review of the literature, an association was noted between invasive ovarian 
cancer and endometriosis. Less clear was the association with speciﬁ c histological 
subtypes. The results of our study conﬁ rm the association between invasive ovarian 
cancer-risk and endometriosis. We have further shown that this association is restricted to 
speciﬁ c subtypes as suggested by previous reports. We have reported precise estimates 
for these associations and have identiﬁ ed an association with low-grade serous ovarian 
cancer that, to our knowledge, was not reported previously. We have further shown that 
the risk of clear-cell ovarian cancer is stronger than that for endometrioid ovarian cancer. 
We also included borderline tumours in our analysis and noted no association with risk of 
ovarian cancer. On the basis of evidence, including the results of molecular studies, 
endometriosis should be thought of as a precursor lesion for clear-cell and endometrioid 
ovarian cancers, whereas the type of association with low-grade serous ovarian cancers 
requires further follow-up.
Clinicians need to be aware of the increased risk of speciﬁ c ovarian cancer subtypes in 
women with endometriosis. The hope is that we will develop a risk stratiﬁ cation model that 
combines genetic and epidemiological risk to better stratify women into high-risk, 
intermediate-risk, and low-risk categories, allowing better individualisation of prevention 
and early detection approaches such as risk-reduction surgery and screening. The 
importance of the work is shown in its power to better deﬁ ne the role of endometriosis in 
the cause of ovarian cancer. We are learning that ovarian cancer is not one disease, but 
rather several diseases with distinct molecular and epidemiological causes. A better 
understanding of the cause of the various disease subsets is necessary if we hope to develop 
better prevention, screening, and treatment approaches for this heterogeneous disease.
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co-occurrence of endometriosis with endometrioid and 
clear-cell ovarian tumours and molecular and genetic 
similarities between these disorders. Future research 
should focus on identi ﬁ cation of factors that are associated 
with malignant transformation of endometriosis and 
subsequent risk of low-grade serous, clear-cell, and 
endometrioid ovarian cancers to identify women for 
whom more deﬁ nitive endometriosis treatment and 
ovarian cancer surveillance would be appropriate (panel).
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